The European Chemicals Agency (ECHA) has confirmed the French regulatory authority ANSES’s proposal to classify cannabidiol as reproductive toxic. The recommendation calls for classification in Category 1B with hazard statements H360FD and H362. For the European CBD industry, with annual sales around €2.5 billion, this step represents an existential threat, as Article 15 of the EU Cosmetics Regulation fundamentally prohibits reproductive toxic substances in Categories 1A and 1B in cosmetic products.
📑 Inhaltsverzeichnis
The background involves a submission from the French National Food, Environmental and Occupational Health Agency (ANSES) from 2025. The ECHA’s Member State Committee largely followed the ANSES assessment in March 2026. The basis consists of animal studies on rats with dosages of 300 milligrams per kilogram of body weight, in which researchers documented impairments to fertility and embryonic development. The industry association European Industrial Hemp Association (EIHA) has announced it will challenge the classification using all available means and instead demand the weaker Category 2.
What Category 1B Means in Practice
The CLP Regulation 1272/2008 recognizes three levels for reproductive toxicity. Category 1A designates damage proven in humans, Category 1B stands for a suspected effect based on animal experimental data, and Category 2 indicates suspicion without sufficient substantiation. The ECHA recommendation places cannabidiol in the middle tier, thereby determining that the substance presumably impairs human reproductive capacity, can harm the unborn child, and can affect nursing infants through breast milk. The hazard statements H360FD and H362 require labeling and automatically trigger downstream regulatory consequences.
The classification hits the cosmetics industry hardest. Article 15 of the EU Cosmetics Regulation 1223/2009 prohibits the use of CMR substances in Categories 1A and 1B in cosmetic products without express exemption. Skin creams, salves, shampoos, and massage oils with cannabidiol would lose their marketability across the entire EU internal market once the classification takes effect. In France alone, this threatens approximately 15,000 jobs and 2,500 specialized retail shops with a sales volume of €200 million, according to estimates by the Union of Vape and CBD Industry (UIVEC).
Consequences for Food and Dietary Supplements
Beyond cosmetics, food and supplements are affected. The ongoing Novel Food procedures at EFSA are already under pressure after the authority defined a safety value of 0.0275 milligrams per kilogram of body weight per day in February 2026. We reported extensively on this in our report on EFSA’s safety value determination. An additional Repr. 1B classification would sharpen EFSA’s already restrictive stance and could effectively stall over 200 pending applications.
Francesco Mirizzi of the EIHA emphasizes that the procedure is not yet concluded. ECHA’s Risk Assessment Committee is currently reviewing feedback from the public consultation and will subsequently submit a formal opinion to the EU Commission. Only the Commission will ultimately decide on including the classification in Annex VI of the CLP Regulation. The timeframe is estimated at three to nine months. Zoé Demange of UIVEC warns of immediate and largely irreversible consequences for the sector if the Commission follows the ECHA recommendation.
Significance for the German-Speaking Market
A harmonized EU classification applies directly in all member states, including Germany and Austria. Switzerland typically follows the CLP Regulation through its Chemical Act (ChemG), though with some delay. For German CBD manufacturers in the cosmetics sector—such as producers of hemp salves or CBD massage oils—the ban would take effect without transition period. For dietary supplements, much depends on the outcome of parallel Novel Food procedures. Hemp leaf extracts with very low CBD concentrations and cosmetics with hemp seed oil would likely not be affected, as they are not classified as CBD-containing products in the strict sense.
The EIHA argues in its statement to the Commission that the ANSES study data is insufficient to justify the high threshold of Category 1B. A Category 2 classification would trigger labeling requirements but avoid the automatic cosmetics ban. Jacopo Paolini, who works at Enecta and is active in the EU association structure Copa-Cogeca, calls for differentiated consideration of various CBD concentrations and application forms. The EIHA has previously successfully opposed restrictive CBD interpretations and now plans a similar step before the EU Commission.
Timeline and Next Steps
After the RAC vote, the recommendation goes to the EU Commission, which prepares an Implementing Act. This is followed by consultation with member states in the REACH regulatory committee. Upon positive vote, the classification is adopted as an Adaptation to Technical Progress in Annex VI of the CLP Regulation. The transition period typically lasts 18 months from entry into force. The industry thus has a limited window to reformulate products, identify alternative active substances, or apply for exemptions for particularly high concentrations.
Frequently Asked Questions
What does Category 1B classification concretely mean for consumers?
As long as the EU Commission has not incorporated the ECHA recommendation into Annex VI of the CLP Regulation, existing CBD products remain approved and legal. Only with the formal Implementing Act and after the typically 18-month transition period do prohibitions take effect. Consumers need not fear immediate consequences, but should be aware that the product landscape will change significantly in the medium term.
Are all CBD products equally affected?
No. The cosmetics ban under Article 15 hits products with isolated or concentrated CBD hardest. Hemp seed oil, which naturally contains no CBD, is unaffected. For food products, the assessment depends on the parallel Novel Food procedure. Medicinal products with market approval, such as Epidyolex, are subject to their own pharmaceutical regulatory framework and are formally not covered by the CLP classification.
What arguments does the industry present against the classification?
The EIHA points to the high dose of 300 milligrams per kilogram in animal studies, which represents many times realistic human exposure. Additionally, the association criticizes that human epidemiological data is underrepresented in the ANSES submission. The demand is to classify cannabidiol in Category 2 instead of 1B, which would preserve labeling requirements but avoid the automatic cosmetics ban.
When will the EU Commission make its final decision?
According to the industry association EIHA, the EU Commission will decide within three to nine months after submission of the RAC opinion. Realistically, a formal classification is expected by late 2026 or early 2027. Until then, lobby negotiations with the Commission and member states continue in parallel.
How are German manufacturers responding to the threatened classification?
German manufacturers of CBD cosmetics are examining alternative active substances such as hemp seed oil, hemp leaf extracts, or isolated terpenes. Larger providers such as Sanity Group and Synbiotic had already scaled back their CBD cosmetics investments before the ECHA recommendation. The focus is shifting toward pharmaceutical medicinal cannabis products, which are formally not covered by the CLP classification.
Sollte CBD trotz der ECHA-Einstufung in Kosmetik erlaubt bleiben?
Sources: Business of Cannabis 15.05.2026, ANSES Press Release 2025, ECHA Substance Information cannabidiol, BAV Institute Classification Dossier, EIHA Statement.
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
